anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a medicine compound having the functions of aging resistance and/or immunoregulation. The medicine compound is a pharmaceutical product made of raw materials such as vitamin C, grape seed extract OPC, fructus crataegi, topaz, Rhizoma Polygonatum, wolfberry fruit and fructo-oligosaccharides. The invention also provides a preparation method for the medicine compound and an application of the medicine compound. The medicine compound which organically integrates antioxidants such as vitamin C and so on and Chinese traditional medicine can comprehensively regulate the immunologic function of a human body, remove oxygen-derived free radicals in the human body, increase the activity of SOD in cells, inhibit LPO generated in a liver, reduce the production of toxic substance and promote the excretion of toxic substance, thereby having the functions of aging resistance and immunoregulation. The composition and usage of the raw materials reach the aim of synergism in coordination. The medicine provides a new clinic or food choice.
The invention provides a drug-loaded liposome which comprises long-circulating liposome and pharmaceutically active ingredients wrapped in the long-circulating liposome, wherein the pharmaceutically active ingredients comprise paclitaxel and resveratrol. The invention further provides a preparation method of the drug-loaded liposome. The method comprises, by using a thin film-ultrasonic method, preparing liposome sources, distearoyl phosphatidyl ethanolamine-methoxy polyethylene glycol 2000 and the pharmaceutically active ingredients into the drug-loaded liposome, wherein the pharmaceutically active ingredients comprise the paclitaxel and the resveratrol. The invention further provides the drug-loaded liposome prepared by the invention. In addition, the invention provides an application of the liposome in preparing antitumor drug and in treating the tumor. The drug-loaded liposome contains the paclitaxel and the resveratrol, has activity of inhibiting development of drug-sensitive tumor, furthermore effectively inhibits development of chemotherapeutic-drug-resistance tumor, and has great clinical value.
Digoxin has a narrow therapeutic index, increased monitoring of serum digoxin concentrations and for potential signs and symptoms of clinical toxicity is necessary when initiating, adjusting, or discontinuing drugs that may interact with digoxin. Prescribers should consult the prescribing information of any drug which is co-prescribed with digoxin for potential drug interaction information.

7.1 P-Glycoprotein (PGP) Inducers/Inhibitors   
Digoxin is a substrate of P-glycoprotein, at the level of intestinal absorption, renal tubular section and biliary-intestinal secretion. Therefore, drugs that induce/inhibit P-glycoprotein have the potential to alter digoxin pharmacokinetics.

7.2 Pharmacokinetic Drug Interactions   
Pharmacokinetic interactions have been observed and reported primarily when digoxin is co-administered by oral route. There are very few studies that have evaluated the drug interaction when digoxin is administered via IV route. The magnitude of digoxin exposure change through IV route is generally lower than that through oral route. Table below provides available interaction data using digoxin IV formulation (NA means not available).

7.3 Potentially Significant Pharmacodynamic Drug Interactions   
Because of considerable variability of pharmacodynamic interactions, the dosage of digoxin should be individualized when patients receive these medications concurrently.

7.4 Drug/Laboratory Test Interactions   
Endogenous substances of unknown composition (digoxin-like immunoreactive substances [DLIS]) can interfere with standard radioimmunoassays for digoxin. The interference most often causes results to be falsely positive or falsely elevated, but sometimes it causes results to be falsely reduced. Some assays are more subject to these failings than others. Several LC/MS/MS methods are available that may provide less susceptibility to DLIS interference. DLIS are present in up to half of all neonates and in varying percentages of pregnant women, patients with hypertrophic cardiomyopathy, patients with renal or hepatic dysfunction, and other patients who are volume-expanded for any reason. The measured levels of DLIS (as digoxin equivalents) are usually low (0.2-0.4 ng/mL), but sometimes they reach levels that would be considered therapeutic or even toxic.

In some assays, spironolactone, canrenone, and potassium canrenoate may be falsely detected as digoxin, at levels up to 0.5 ng/mL. Some traditional Chinese and Ayurvedic medicine substances like Chan Su, Siberian Ginseng, Asian Ginseng, Ashwagandha, or Dashen can cause similar interference.

Spironolactone and DLIS are much more extensively protein-bound than digoxin. As a result, assays of free digoxin levels in protein-free ultrafiltrate (which tend to be about 25% less than total levels, consistent with the usual extent of protein binding) are less affected by spironolactone or DLIS. It should be noted that ultrafiltration does not solve all interference problems with alternative medicines. The use of an LC/MS/MS method may be the better option according to the good results it provides, especially in terms of specificity and limit of quantization.
PROBLEM TO BE SOLVED: To provide a pharmaceutical object emitting coating for use in therapeutical apparatus in which a pharmaceutical object and polymer are turned into solution easily and a method to apply pharmaceutical/polymer coating without risk that the pharmaceutical and polymer are coupled in the common solution or suspension. SOLUTION: A pharmaceutical object emitting coating is applied so that polymer is dissolved in a first solvent (solvent A) to form a polymer system while pharmaceutical object is dissolved or suspended in a second solvent (solvent B) to form a pharmaceutical system. The prepared coating or coating layer consists of a substantially uniform coupling of the pharmaceutical and polymer. The solvent B may the same as or different from the solvent A. The coating can be applied to a stent by spraying or immersing the polymer system and pharmaceutical system separately onto the thereapeutical apparatus concerned. The coating can be completed by applying the polymer and pharmaceutical systems either simultaneously or one after another.
The invention discloses a safe and efficient tetrodotoxin compound preparation with the anti-arrhythmic effect and a preparation method thereof. The tetrodotoxin compound preparation comprises tetrodotoxin, lidocaine hydrochloride, cosolvents, freeze-drying excipients and stabilizing agents. The freeze-drying excipients are mannitol. The stabilizing agents are dextran or beta-cyclodextrin. The cosolvents are citron acid. The preparation can remarkably reduce the death rate caused by rat aconitine model arrhythmia, is particularly suitable for rescuing severe-case arrhythmia patients and can be used for developing new anti-arrhythmic drugs. The preparation is stable in quality, efficient during clinical use and good in safety performance.
<P>PROBLEM TO BE SOLVED: To provide a human amnion-derived mesenchymal cell having a high hypoglycemic effect and a new diabetic medicine useful for treating diabetes.  <P>SOLUTION: The human amnion-derived mesenchymal cell is immortalized by transferring an exogenous immortalized gene (e.g. TERT gene or E6 gene and E7 gene of human papillomavirus) to the cell. The immortalized human amnion-derived mesenchymal cell develops a remarkable hypoglycemic action. The immortalized human amnion-derived mesenchymal cell is used as an active ingredient for a diabetic medicine.  <P>COPYRIGHT: (C)2010,JPO&INPIT
This research protocol will evaluate subjects with systemic lupus erythematosus (SLE) and their relatives to study the pathogenesis and natural history of the disease and the mechanisms leading to enhanced organ damage. Patients will be evaluated by a history and physical examination and routine laboratory studies will be obtained as needed to assess disease activity or complications of the disease and to monitor for drug-related toxicities. Blood, skin or urine specimens may be requested for research purposes, including genetic studies. In addition, a subset of these patients will undergo several tests to understand the pathogenic changes affecting their blood vessels. Patients who are eligible for other research protocols will be offered the opportunity to participate in these studies by signed informed consent. Any medical care recommended or provided to the patient will be consistent with routine standards of practice and provided in consultation with the patient s referring physician. Blood and urine samples and cardiovascular testing will also be collected or applied to from healthy volunteers for research purposes and to support the identification and validation of new biomarker candidates.
The invention concerns a human Von Hippel Lindau tumour suppressor gene 14 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumour, hemopathy, disorder of development, infection of HIV, immunological diseases and a variety of inflammation etc. utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes a human Von Hippel Lindau tumour suppressor gene 14.
Many patients with advanced lung cancer and their caregivers struggle with treatment decisions, such as when to say "enough." Patient preparation for facing termination of cancer-directed therapy for the number one cause of cancer mortality for both men and women in the U.S. is not well handled in most clinical practices. Sparse literature validates that this concern is often denied by investigators. Failure to engage in a systematic, informed decision-making process, even in the initial stage of treatment, may often result in patients looking back and saying, "Knowing what I know now, I wouldn't make the same choice" The long-term goal of this program of research is to enhance patient care for lung cancer by oncology health professionals and to promote patient empowerment to make informed choices, defined as the ability to actively understand and influence one's health status. For this study, shared decision making is defined as a tailored, interactive process (emphasizing beliefs/personal values) in which the patient is informed enough to ask pertinent questions and to participate in the final decision at his/her own preference and comfort levels. The intent is to test a decision aid for patients with advanced lung cancer to help facilitate informed decisions about treatments that affect quality of life, including termination of cancer-directed treatment.
The invention provides a 125I radioactive microsphere. The 125I radioactive microsphere comprises a sphere shell and a solution which contains 125I and is wrapped in the sphere shell. The sphere shell is made of materials which comprise paclitaxel and tripropylene glycol dipropyl acrylate. The 125I radioactive microsphere is stable in structure, and compared with adsorption carriers used in a traditional adsorption method, raw materials adopted by the 125I radioactive microsphere are more economical; meanwhile, due to the fact that radioactive 125I nuclide is wrapped in the sphere shell of the microsphere, the utilization efficiency of the 125I radioactive microsphere is close to 100 percent and higher than that of the traditional adsorption method. The invention further provides a preparation method for the 125I microsphere and a microflow device. By adjusting the flow of a colloidal nucleus phase, a capsule wall phase and a continuous phase, the accurate controllability of the 125I radioactive microsphere particle size is achieved. Compared with the traditional method which is more prone to being influenced by experimental environment factors, the controllability of the 125I radioactive microsphere and the preparation method thereof and the microflow device is high.
PURPOSE:To enhance the productivity while the handle ability increases, and reduce variations in void percentage, in weight and in size of a tablet by molding a resin film so as to form a container, and excessively filling moistened powder in the container while leveling the outer surface of the moistened powder filled under pressure. CONSTITUTION:A resin film 14 for molding a container, is paid out from a reel 15, and is then heated by a heating device 16. Thereafter, the resin film 14 is pushed into a mold hole 6 in a die on an endless belt device 5 so as to form a container 36. Meanwhile, a moistened powder material is fed in feed holes 11 of a turntable 3 from a hopper 12, and thereafter, is superposed on the container 36 while a feed rod 19 of a feeding and pressurizing device 19 is lowered so that the moistened powder is filled under pressure into the container 36 from the feed holes 11. A forming rod 21 of a forming device 22 is lowered so as to chamfer the outer surface of the moistened powder, and thereafter, the container 36 is parted from the dies 10, and is then shifted onto a conveying tray 37. After drying by a drying device 29, the moisture member is cut into pieces by a cutting device.
PROBLEM TO BE SOLVED: To obtain a medicinal composition stable during production and during preservation thereafter, and good in elutability by covering or mixing a specific amount of hydrophobic low melting-point material on or with an active ingredient, and carrying out a compression molding of the obtained particles with a goodly moldable material. SOLUTION: This medicinal composition is obtained by covering or mixing 0.01-1 pts.wt. hydrophobic low melting-point material (preferably having <=100 deg.C melting point, e.g. stearic acid) on or with 1 pts.wt. active ingredient (preferably an effective component of a medicine having the stability after the compression molding lowered from the stability before the compression molding when carrying out the compression molding, e.g. nicorandil), and carrying out a compression molding of the obtained particles with a goodly moldable material [preferably, the one capable of providing a tablet having >=4 kg hardness when pressing 200 mg material under 2,000/cm2 pressure in a mold having 8 mm diameter, and <=30 min corruption time in a corruption test of the pharmacopoeia of Japan (13 section), and being inert to a medicine, e.g.  granulated lactic acid, and preferably added to a preparation at >=10 wt.%] under 20-65 kg/mm2 pressure.
Research on the local hippocampal atrophy for early detection of dementia has gained considerable attention. However, accurately quantifying subtle atrophy remains challenging in existing morphological methods due to the lack of consistent biological correspondence with the complex curving regions like the hippocampal head. Thereby, this article presents an innovative axis-referenced morphometric model (ARMM) that follows the anatomical lamellar organization of the hippocampus, which capture its precise and consistent longitudinal curving trajectory. Specifically, we establish an "axis-referenced coordinate system" based on a 7 T ex vivo hippocampal atlas following its entire curving longitudinal axis and orthogonal distributed lamellae. We then align individual hippocampi by deforming this template coordinate system to target spaces using boundary-guided diffeomorphic transformation, while ensuring that the lamellar vectors adhere to the constraint of medial-axis geometry. Finally, we measure local thickness and curvatures based on the coordinate system and boundary surface reconstructed from vector tips. The morphometric accuracy is evaluated by comparing reconstructed surfaces with those directly extracted from 7 T and 3 T MRI hippocampi. The results demonstrate that ARMM achieves the best performance, particularly in the curving head, surpassing the state-of-the-art morphological models. Additionally, morphological measurements from ARMM exhibit higher discriminatory power in distinguishing early Alzheimer's disease from mild cognitive impairment compared to volume-based measurements. Overall, the ARMM offers a precise morphometric assessment of hippocampal morphology on MR images, and sheds light on discovering potential image markers for neurodegeneration associated with hippocampal impairment.
Metastasis lesion will be treated with a SBRT of 30Gy/5F from day 1 to day 5 . Injection of Immunological Agenthuman recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle.Subcutaneous injection of Peginterferon alfa-b2(90ug) will be executed in day8. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle. Injection of Peginterferon alfa-b2(90ug) will be executed in day8 of this cycle.
Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticulate formulations for photodynamic therapy comprising a hydrophobic photosensitizer, human serum albumin (HSA) and stabilizing agent are provided. These nanoparticulate formulations provide therapeutically effective amounts of photosensitizer (PS) for parenteral administration. In particular, tetrapyrrole derivatives can be used as photosensitizers whose efficacy and safety are enhanced by such nanoparticulate formulations. A method of preparing the HSA-based nanopar cles under sterile conditions is also provided. In one of the preferred embodiments of the present invention temoporfin, a hydrophobic PS, is formulated as a nanoparticle for parenteral administration.; The formulations are useful for treating hyperplasic and neoplasic conditions, inflammatory problems, and more specifically to target tumor cells.
PURPOSE:To provide the titled composition containing extract of mycelia of Cortinellus shiitake as an active component and especially effective in suppressing the proliferation of bacteria and improving immunity of the skin itself. CONSTITUTION:Cortinellus shiitake is inoculated in a solid medium containing baggasse as a base and the mycelia are proliferated to obtain a solid medium containing mycelia. The medium is disintegrated, added with water and optionally an enzyme such as cellulase and crushed and ground to effect the extraction of the active component. After the extraction treatment, the product is heated at 95 deg.C to inactivate the enzyme and sterilize the medium and obtain an extract of the mycelia of Cortinellus shiitake. The objective beauty wash composition for the remedy of atopic dermatitis can be produced by adding the extract as an active component to a composition containing a humectant such as an alcohol (e.g. ethanol), glycerol, etc., an emollient such as ester oil and other solubilizing agent, etc. The composition gives extremely low irritation to the skin, has remarkably high safety and imparts smoothness and moistness to the skin.
INTRODUCTION: Sleep plays a crucial role in maintaining health. Transplant patients are exposed to numerous stressors and are at risk of sleep disturbances. The aim of this study was to assess the sleep patterns of transplant patients.
METHODS: An anonymous paper survey was carried out among patients from one transplant center in Poland. Respondents were asked about the quality and quantity of sleep and the overall impact of the transplantation on their night rest. Data were collected from June to November 2023.
RESULTS: Data were obtained from 212 respondents (122 males and 90 females), aged 48.38 ± 13.68. The positive impact of transplantation on sleep hygiene was indicated by 57.4% of respondents, 28.9% observed no impact, and 13.6% rated the impact as negative. Our study showed that sleep is more satisfying in males than in females (62.8% of males and 46.7% of females). The analysis revealed that 38.9% of females need 30 minutes more than men to fall asleep. Additionally, females tend to get up half an hour later compared to men. About 71.9% of males declared good well-being the next day compared to 62.2% of females. Furthermore females declared more sleepiness the next day. The study also showed that older transplant recipients (over 50 years-of-age) report more frequent awakenings at night.
CONCLUSIONS: The data collected showed differences in sleep patterns according to gender and age. Females and older patients should be screened for sleep disturbances during post-transplantation care.
Eligible participants assigned to the Dietary Guidelines for Americans (DGA) arm will adhere to the Dietary Guidelines for Americans in addition to any ongoing medications (e.g., mood stabilizers and/or second-generation antipsychotics). Participants will receive weekly and as needed diet counseling from a registered dietician. Participants will be asked to monitor and report their blood ketone levels each day via a finger-prick device provided by the study team. Participants have the ability to opt into an optional open label phase where they can switch to the ketogenic diet with the daily finger pricks for 12 weeks after the 12-week main study.
MW ablation performed either laparoscopically or percutaneously is a safe, effective, and minimally invasive technique for the management of hypersplenism in patients with liver cirrhosis. It may significantly increase platelet count and white blood cell (WBC) count and improve hepatic blood supply with fewer complications. Ablating more than 40% of the splenic parenchyma may yield better long term results. This method may provide a new and promising minimally invasive alternative for treating hypersplenism.
Since the identification of human immunodeficiency virus type 1 (HIV-1) in 1983, many improvements have been made to control viral replication in the peripheral blood and to treat opportunistic infections. This has increased life expectancy but also the incidence of age-related central nervous system (CNS) disorders and HIV-associated neurodegeneration/neurocognitive impairment and depression collectively referred to as HIV-associated neurocognitive disorders (HAND). HAND encompasses a spectrum of different clinical presentations ranging from milder forms such as asymptomatic neurocognitive impairment or mild neurocognitive disorder to a severe HIV-associated dementia (HAD). Although control of viral replication and suppression of plasma viral load with combination antiretroviral therapy has reduced the incidence of HAD, it has not reversed milder forms of HAND. The objective of this review, is to describe the mechanisms by which HIV-1 invades and disseminates in the CNS, a crucial event leading to HAND. The review will present the evidence that underlies the relationship between HIV infection and HAND. Additionally, recent findings explaining the role of neuroinflammation in the pathogenesis of HAND will be discussed, along with prospects for treatment and control.